Your new experience awaits. Try the new design now and help us make it even better

MINI REVIEW article

Front. Aging Neurosci.

Sec. Alzheimer's Disease and Related Dementias

LRP1 at the Crossroads of Aβ Clearance and Therapeutic Targeting in Alzheimer's Disease

Provisionally accepted
Yuepeng  DengYuepeng DengHaolin  YinHaolin YinZihao  LuZihao LuHuan  LanHuan LanWenxiong  LiuWenxiong LiuChao  ZuoChao ZuoNanfang  PanNanfang PanXiaohe  TianXiaohe Tian*Qiyong  GongQiyong Gong
  • West China Hospital of Sichuan University, Chengdu, China

The final, formatted version of the article will be published soon.

Alzheimer's disease (AD), characterized by progressive cognitive decline, memory impairment and behavioral disturbances, is the most common form of dementia, and no disease-modifying treatments are available to halt or slow its progression. Amyloid-beta (Aβ) is suggested to play a pivotal role in the pathogenesis of AD, and enhancing the clearance of Aβ from the brain has emerged as a major research direction. As the primary receptor for Aβ clearance at the blood-brain barrier (BBB), low-density lipoprotein receptor-related protein 1 (LRP1) plays a crucial role in regulating Aβ transport and metabolism. Understanding the mechanisms through which LRP1 functions, as well as the factors that influence its activity is essential for enhancing Aβ clearance from the brain and developing targeted therapeutic strategies for Alzheimer's disease. In this review, we introduce the transport of Aβ across the BBB, followed by a discussion of the basic structure and function of LRP1 and its role in AD progression. Then, we summarize factors affecting LRP1 function and current advances in LRP1-targeted therapies. Finally, we explore the potential of LRP1 as a therapeutic target for AD. So, LRP1 may be a central modulator of Aβ dynamics and a clinically actionable target for treatment of Alzheimer's disease.

Keywords: Alzheimer's disease (AD), beta-amyloid (Aβ), Blood-brain barrier (BBB), Low-density lipoprotein receptor-related protein 1 (LRP1), targeted therapy

Received: 19 Jul 2025; Accepted: 17 Nov 2025.

Copyright: © 2025 Deng, Yin, Lu, Lan, Liu, Zuo, Pan, Tian and Gong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Xiaohe Tian, xiaohe.t@ahu.edu.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.